A Study to Assess Multidomain Endpoints of an ECG Patch

Clinical Observational Study of Remote, Non-invasive, Multidomain Endpoints in Patients Recovering From Acute Decompensated Heart Failure

This study aims to evaluate the utility of a wearable heart monitoring patch that can be worn on the body to collect various measurements related to heart failure and develop a concept to potentially be used as a new measurement. It is crucial to test out new ways that make it easier to do research for new drugs and increase our chances of knowing how well they will work early on in the development process. Results from this study will be useful in planning future development programs for drugs aimed at treating patients with heart disease.

This study will be conducted in three hospitals, it is non-randomised (not chosen by chance), exploratory, study in the United Kingdom. It aims to involve up to 80 men and women recently admitted due to sudden, severe heart failure symptoms. Participants will be part of the study for about two months, with one hospital visit after discharge, as commonly done in heart failure centres.

• Visit 1 (Pre-Screening/Screening/Enrolment) will assess the participant's eligibility for participating in the study and for collecting data following hospitalisation for acute decompensated heart failure (ADHF). Participants will be trained and receive an ECG patch to wear from that moment onwards at home for a period of 4 to 7 days.
• Visit 2 (Follow-up visit) will be conducted approximately 6-8 weeks post Visit 1 and this will be the final study-related site visit. Participants will receive an ECG patch to wear at home for a second time for a period of 4 to 7 days.
• Review of Medical Records: It is a review of the health status using medical records by the study team. The participant is not expected to attend the hospital for any appointments

Inclusion Criteria:

• Men and women aged 18 years or older
• Confirmed diagnosis of heart failure according to the latest ESC criteria
• Primary cause of hospitalisation due to decompensated heart failure
• Willing and able to complete all visits and assessments as per protocol
• Provision of signed and dated, written informed consent before any study-specific procedures.

Exclusion Criteria:

• Receiving renal replacement therapy
• Implanted cardiac (or other) device in-situ, cardiac pacemaker, defibrillator, or other implanted electronic devices or other ventricular assist device in situ
• Currently receiving chemotherapy
• Receiving end-of-life care
• Active severe infection: individuals with an active severe infection, as determined by the PI's clinical judgment, will not be eligible for study participation
• Hypersensitivity to patch adhesive/ materials in the patch
• Skin condition or damage that prevents wearing of the patch.